Literature DB >> 8350115

Vigabatrin and depression.

H A Ring1, R Crellin, S Kirker, E H Reynolds.   

Abstract

Ten patients who developed a major depressive episode in association with vigabatrin treatment for intractable epilepsy are reported. The depression usually occurred early in the course of treatment, but when delayed followed a recent increase in dose. Depressive symptoms occurred at doses varying between 1.5 g and 4 g a day, often but not always when patients were experiencing a decrease in their seizure frequency. Most patients had a history of affective disturbance, sometimes in association with other GABAergic drugs. The observations support a possible role for GABAergic mechanisms in the biology of mood disorders.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350115      PMCID: PMC1015155          DOI: 10.1136/jnnp.56.8.925

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  [EPILEPSY AS A CONVULSIVE DISORDER AND AS A PSYCHOSIS. ON ALTERNATIVE PSYCHOSES OF PARANOID NATURE IN "FORCED NORMALIZATION" (LANDOLT) OF THE ELECTROENCEPHALOGRAM OF EPILEPTICS].

Authors:  H TELLENBACH
Journal:  Nervenarzt       Date:  1965-05       Impact factor: 1.214

2.  gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain.

Authors:  T L Perry; S J Kish; S Hansen
Journal:  J Neurochem       Date:  1979-06       Impact factor: 5.372

3.  CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa.

Authors:  R H Gerner; T A Hare
Journal:  Am J Psychiatry       Date:  1981-08       Impact factor: 18.112

4.  Intravenous GABA administration is anxiogenic in man.

Authors:  J I Nurnberger; W H Berrettini; S Simmons-Alling; J J Guroff; E S Gershon
Journal:  Psychiatry Res       Date:  1986-10       Impact factor: 3.222

5.  Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders.

Authors:  K Kasa; S Otsuki; M Yamamoto; M Sato; H Kuroda; N Ogawa
Journal:  Biol Psychiatry       Date:  1982-08       Impact factor: 13.382

6.  Neurophysiological and thermoregulatory effects of capsaicin.

Authors:  L S Rabe; S H Buck; L Moreno; T F Burks; N Dafny
Journal:  Brain Res Bull       Date:  1980 Nov-Dec       Impact factor: 4.077

7.  Plasma GABA levels in psychiatric illness.

Authors:  F Petty; A D Sherman
Journal:  J Affect Disord       Date:  1984-04       Impact factor: 4.839

8.  GABA levels in CSF of patients with psychiatric disorders.

Authors:  B I Gold; M B Bowers; R H Roth; D W Sweeney
Journal:  Am J Psychiatry       Date:  1980-03       Impact factor: 18.112

9.  Emergence of depressive symptoms in patients receiving alprazolam for panic disorder.

Authors:  R B Lydiard; M T Laraia; J C Ballenger; E F Howell
Journal:  Am J Psychiatry       Date:  1987-05       Impact factor: 18.112

10.  Plasma GABA in affective illness. A preliminary investigation.

Authors:  F Petty; M A Schlesser
Journal:  J Affect Disord       Date:  1981-12       Impact factor: 4.839

View more
  15 in total

Review 1.  Suicidality in epilepsy and possible effects of antiepileptic drugs.

Authors:  Marco Mula; Gail S Bell; Josemir W Sander
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 2.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Anticonvulsant-induced psychiatric disorders. The role of forced normalisation.

Authors:  M R Trimble
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

4.  Rapid aggravation of aphasia by vigabatrin.

Authors:  R Gil; J P Neau
Journal:  J Neurol       Date:  1995-03       Impact factor: 4.849

Review 5.  Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 6.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 7.  Metabolism and excretion of mood stabilizers and new anticonvulsants.

Authors:  T A Ketter; M A Frye; G Corá-Locatelli; T A Kimbrell; R M Post
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 8.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 9.  Negative effects of antiepileptic drugs on mood in patients with epilepsy.

Authors:  Marco Mula; Josemir W Sander
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 10.  The promise of new antiepileptic drugs.

Authors:  John S Duncan
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.